Altamira Therapeutics Ltd. (NASDAQ: CYTO)
$0.5100
+0.0294 ( +6.12% ) 14.9K
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
Market Data
Open
$0.5100
Previous close
$0.4806
Volume
14.9K
Market cap
$1.85M
Day range
$0.4860 - $0.5200
52 week range
$0.4500 - $17.2000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 2 | Oct 04, 2024 |
6-k | Form 6-K | 53 | Sep 24, 2024 |
6-k | Form 6-K | 9 | Sep 19, 2024 |
20-f/a | Annual reports | 20 | Jul 01, 2024 |
6-k | Form 6-K | 1 | May 16, 2024 |
20-f/a | Annual reports | 161 | Apr 22, 2024 |
6-k | Form 6-K | 6 | Apr 16, 2024 |
6-k | Form 6-K | 2 | Apr 10, 2024 |
20-f | Annual reports | 166 | Apr 10, 2024 |
6-k | Form 6-K | 2 | Jan 19, 2024 |